Wolverine Asset Management’s AstraZeneca AZN Stock Holding History

Wolverine Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,400	Closed	-$929K	–	1420
2017 Q4	$929K	Hold	13,400	–	–	0.01%	747
2017 Q3	$907K	Sell	13,400 -297,400	-96%	-$18.8M	0.01%	691
2017 Q2	$21.2M	Buy	310,800 +78,900	+34%	+$5.15M	0.27%	82
2017 Q1	$14.4M	Buy	231,900 +192,100	+483%	+$11.2M	0.22%	97
2016 Q4	$2.17M	Buy	+39,800	New	+$2.26M	0.03%	388
2013 Q3	–	Sell	-63	Closed	-$3K	–	2670
2013 Q2	$3K	Buy	+63	New	+$3.21K	﹤0.01%	2435

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Wolverine Asset Management's AZN Position: Q1 2026 in Review

Wolverine Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,872 shares — an estimated $344K sold.

Wolverine Asset Management first reported a position in AZN in Q2 2013 and held it in 40 quarters. The position peaked at $462K in Q3 2013. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Wolverine Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 1,872 AstraZeneca shares in Q1 2026, an estimated $344K.
Wolverine Asset Management first reported a position in AstraZeneca in Q2 2013 and held it in 40 quarters.
Wolverine Asset Management's AstraZeneca position peaked at $462K in Q3 2013.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.